On 5th May 2017, Edaravone drug approved to slow functional failure in patients with Amyotrophic Lateral Sclerosis also called Lou Gehrig Disease by US Food and Drug Administration. Edaravone, a neurotrophic drug, is recommended to improve routine activity and ability. Edaravone is also prescribed to treat functional disorders. In 2015, the Edaravone drug was first approved to treat ALS in Japan and Korea. The FDA quickly involved the creator in applying for approval in the US, after knowing Edaravone’s use in Japan region. Dr. Bastings said, “This is the first new treatment approved by the FDA for ALS in many years, and we are pleased that people with ALS will now have an additional option”.
The drug run by a healthcare professional. Its first treatment period consists for next 14 days on daily basis. During this cycle, the patient gets 10 doses over a period of days and then abandon the drug over a couple of days. The Food and Drug Administration stated that the drug was powerful based on the 6-month clinical trial. The FDA said, “At week 24, individuals receiving Edaravone declined less on a clinical assessment of daily functioning compared to those receiving a placebo”. Some side effects of the drug involve swelling; shortness of breath require treatment. The opposing events stated by members in the medical test were Bruising and gait disturbance.